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Abstract 
Introduction: Postpartum Depression (PPD) affects up to 19% of all women after parturition. 
The nonapeptide oxytocin (OXT) is involved in adjustment to pregnancy, maternal behavior 
and bonding. Our aim was to examine the possible association between plasma OXT during 
pregnancy and the development of PPD symptoms. 
Method: 74 healthy, pregnant women were included in this prospective study. During the 
third trimester of pregnancy and within two weeks after parturition PPD symptoms were 
assessed using the Edinburgh Postnatal Depression Scale (EPDS). Blood samples for plasma 
OXT assessment were collected in the third trimester. Following the literature, participants 
with postpartum EPDS scores of 10 or more were regarded as being at risk for PPD 
development (rPPD group). In a logistic regression analysis plasma OXT was included as a 
potential predictor for being at risk for PPD. Results were controlled for prepartal EPDS 
score, sociodemographic and birth-outcome variables. 
Result: Plasma OXT concentration in mid-pregnancy significantly predicted PPD symptoms 
at two weeks postpartum. Compared to the no-risk-for-PPD group, the rPPD group was 
characterized by lower plasma OXT concentrations. 
Conclusion: To our knowledge, this is the first study to show an association between 
prepartal plasma OXT concentration and postpartal symptoms of PPD in humans. Assuming a 
causal relationship, enhancing OXT release during pregnancy could serve as a potential target 
in prepartum PPD prevention and help to minimize adverse effects of PPD on the mother-
child-relationship.  
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Introduction 
Postpartum Depression (PPD) affects up to 19% of all mothers and adversely influences 
maternal adaptation to motherhood (Gavin et al, 2005) with negative effects on child 
development, as children of depressive mothes are more vulnerable to develop mental 
disorders in later life (Grace et al, 2003).  
The etiology of PPD is closely related to psychological determinants and experiences during 
pregnancy (O'Hara and Swain, 1996). Identification of psychological risk factors for PPD has 
been an important issue in the recent years. Major identified risk factors are a history of 
previous PPD or affective illnesses in general, stressful life events, lack of social support and 
low self-esteem (Beck, 2006; Robertson et al, 2004). Additionally, the early postpartum 
period is seen as a time of increased emotional vulnerability, partly caused by dysregulations 
of the endocrinological homeostasis (Wisner and Stowe, 1997). Due to the challenging 
reorganization of physiological processes that comes along with pregnancy and parturition, 
research started to address endocrine factors as potential determinants in the etiology of PPD. 
From animal models of PPD, we know that withdrawal from high doses of estradiol and 
progesterone, comparable to the respective amounts available during pregnancy, is followed 
by depression-like symptoms (Green et al, 2009). Addtionally, the regulation of the 
hypothalamic-pituitary-adrenal (HPA) axis seems to be disturbed in women with PPD 
(Brummelte and Galea, 2010) or short periods of Postpartum Blues (Ehlert et al, 1990). 
However, existing findings are not consistent (Bloch et al, 2003). One biological parameter 
that has not yet been considered in PPD etiology, is the nonapeptide oxytocin (OXT). OXT is 
synthesized in the paraventricular nucleus (PVN) and the supraoptic nucleus (SON) of the 
hypothalamus and released peripherally into the blood and centrally into different brain 
regions (Gimpl and Fahrenholz, 2001). In context of pregnancy, OXT is known for its 
involvement in the process of delivery (Russell et al, 2003) and its physiological role in the 
onset and maintenance of lactation (Sala and Althabe, 1968).  
Beyond its physiological functions in the periphery, animal studies provide evidence for a 
major role of OXT in behavioral adaptation to pregnancy and motherhood. Characteristic 
maternal behaviors (pup-grooming, hover over offspring, respond latency) are impaired, if 
OXT availability is diminished (Higuchi and Kaba, 1997; Olazabal and Young, 2005; 
Pedersen et al, 2006). Furthermore, maternal OXT functioning influences reciprocal affective 
behaviors between mother and offspring in mammalian species (Nelson and Panksepp, 1998). 
Recently, this association was also shown in humans. Parents showing more affectionate and 
stimulatory behaviors in interactions with their children were characterized by higher plasma 
OXT concentrations (Gordon et al, 2010). Further, Feldman et al. (2007) reported 
associations between prepartum assessed OXT concentrations and postpartum maternal 
adaptation. The maternal plasma OXT level, measured during early and late pregnancy, as 
well as in the first month postpartum, predicted maternal behavior (mother’s gaze at infant, 
motherese vocalizations, affectionate touch) in interaction with the child. A study assessing 
plasma OXT twice during pregnancy showed higher postpartum maternal-fetal attachment-
scores in women with a OXT rise between the first and third trimester compared to women 
with stable or decreasing patterns of OXT (Levine et al, 2007). In non-pregnant women, OXT 
is known to promote interpersonal relationships and enhance feelings of love and trust 
(Heinrichs and Domes, 2008).  
Based on current evidence, lower OXT levels in pregnancy could result in impaired emotional 
adaptation to motherhood, which is a major risk factor for PPD development and 
subsequently affects the quality of maternal behavior (Murray et al, 1993; Stein et al, 2010). 
Therefore, the aim of the present study was to assess a potential association between OXT 
during pregnancy and postpartum PPD symptoms in a sample of healthy pregnant women. 
We expected, that lower plasma OXT levels during the third trimester of pregnancy would 
result in an increased risk for PPD, as assessed postpartum. Results could help to elucidate the 
etiopathology of PPD and provide new targets for prepartal prevention of PPD.  
Methods 
Subjects 
Data was collected within a larger longitudinal study conducted with 100 pregnant women in 
the area of Basel, Switzerland. All participants were recruited between their 21st and 32nd 
week of gestation. Recruitment-methods included local newspaper announcements, promotion 
of the study at local hospitals and a call for participants on local TV. A detailed study 
description was given to all interested women and, if any arised, questions were answered. All 
participants were screened for the following inclusion criteria: (a) no current mental illness, 
(b) no severe medical complications (acute or chronic physical diseases, such as gestational 
diabetes, metabolic diseases, hypertension and thyroid dysfunction), (c) no signs of fetal 
malformation, (d) a pre-pregnancy BMI below 32, (e) no smoking beyond the 10th week of 
gestation and (f) good knowledge of German language. Data for analyses of the present paper 
was available for 73 participants, of which 16 were characterized by at least one lifetime 
depressive episode. All cases with a lifetime episode of depression were dated back more than 
two years before participation in the study. A flowchart of dropouts is displayed in Figure 1. 
Comparisons between the 73 women providing complete data and the 27 excluded women 
indicated no significant differences on age, parity, socioeconomic status and PPD symptoms.  
Informed written consent was obtained from all participants. The study protocol was 
approved by the local ethics committee and is consistent with the revised Helsinki Declaration 
of 1975.  
Blood sampling and OXT measurement 
All blood samples were obtained between the 30th and 34th week of gestation. Participants 
visited the study centre for an experimental session, which included blood sampling and other 
physiological assessments. The samples for the OXT assessment were collected at the 
beginning of the session, starting between 1 pm and 3 pm. Participants were seated on a 
examination couch and a study nurse sampled 2.7 ml of blood into vacutainer tubes 
containing lithium heparin and 108 µl of Aprotinin (BioChemica, Germany). Tubes were kept 
on ice and centrifuged within 10 minutes at 6 °C at 3000g for 10 min. Supernatants were 
pipetted into safe-lock devices and stored at -80 °C until analysis. 
Samples were analyzed at the Department of Behavioural Neuroendocrinology, Max Plank 
Institute of Psychiatry, Munich, Germany, using a radioimmunoassay, as described elsewhere 
(Landgraf et al, 1995). This assay was reported to have an antiserum-cross-reactivity of less 
than 0.7%, with a detection limit of 0.1 pg per sample. All samples were analyzed in 
duplicates. The intra-assay and inter-assay coefficients of variability were 6-8% and 8-10%, 
respectively. 
Assessment of demographic and psychological characteristics 
After inclusion, participants were interviewed for assessing possible present, recent or life-
time depression and anxiety disorders using the German translation of corresponding sections 
of the Computer Assisted Personal Interview (CAPI) version of the Composite International 
Diagnostic Interview (Wittchen et al, 1998; Wittchen and Pfister, 1997; World Health 
Organization, 1990) and general socioeconomic data. 
Depressive symptoms were assessed within two weeks after delivery using the Edinburgh 
Postnatal Depression Scale (EPDS), a scale originally developed as a screening measure for 
depression, showing  good reliability (split-half: 0.82; standardized α = .81) (Bergant et al, 
1998). Ten items, dealing with typical PPD symptoms are answered on a 4-point scale. As a 
control variable the prepartal EPDS score was assessed between the 32nd and 34th week of 
gestation.  




All variables were checked for normal distribution, missing data and outliers (defined as more 
than two standard deviations below or above the mean) by the Kolmogorov-Smirnof test and 
visual inspection. Outliers were checked for validity and excluded if reasonable. If necessary, 
variables were subjected to transformation by natural logarithm before further analyses. 
Differences on demographic, biological and psychological characteristics between included 
and excluded study participants were tested by t and χ2 tests. Participants were divided into a 
risk-for PPD group (rPPD) and a no-risk-for PPD group (nPPD), according to the respective 
postpartum EPDS score. Based upon the proposals of Bergant et al. (1998) and Jardri et al. 
(2006), the chosen cut-off score for being at risk for PPD was 10 or more within the first two 
weeks postpartum. T and χ2 tests were computed between the groups, to identify possible 
confounders among the demographical and medical variables. Descriptive statistics of EPDS 
scores and OXT values are reported. The postpartal EPDS scores of nursing and not nursing 
mothers were compared using the t-test. The bivariate correlation was computed between the 
pre- and postpartal EPDS score. The association between OXT and PPD symptoms was tested 
by conducting a binary logistic regression analysis with the group variable as outcome 
variable and OXT concentration as the potential predictor in the first run. In a second run the 
prepartal EPDS score was added, to control for potential confounding by previous depressive 
symptoms. Further analyses were computed including OXT concentration as the first 
predictor and other potential predictors, identified through previous group comparisons. Due 
to the expected, unequal group sizes, every logistic regression analysis was conducted with 
not more than two predictors, of which the first one was always OXT concentration. Because 
accurate classification of participants is difficult when groups are not evenly split, primary 
emphasis was placed on prediction rather than classification of being at risk for PPD. Data 
was analyzed using SPSS 16.0.2 for Mac OS X. The level of significance for all analyses was 
set at α = .05. 
Results 
Sample and group characteristics 
Demographic and pregnancy-related sample and group characteristics are displayed in Table 
1. A group variable was introduced according to the postpartum EPDS score. Fourteen
participants were identified as having a postpartum EPDS score of 10 or more and were 
assigned to the rPPD group, representing a higher risk for the development of PPD. The 
remaining 59 participants were assigned to the nPPD group. Groups were tested for 
significant differences regarding sociodemographic and birth characteristics. Groups differed 
only in length of gestation. Participants in the rPPD group had a significantly shorter length of 
gestation (M = 39.02 weeks) compared to participants in the nPPD group (M = 39.73 weeks) 
(T (71) = 2.049; P < .05). Therefore length of gestation was included as a potential mediator 
in further analysis of the relationship between OXT and PPD symptoms.  
Pre- and postpartal EPDS scores 
Postpartal EPDS scores did not differ between nursing and not nursing mothers (T (69) = 
0.025; P = .98). Prepartal EPDS scores (Range 0-17) were significantly correlated with 
postpartal EDPS scores (Range 0-22) (r = .232; p = .048). Mean prepartal and postpartal total 
EPDS scores were 4.77 and 5.85 respectively.  
Plasma OXT concentrations 
Plasma OXT concentrations had a range of 14.39-245.71 pg/ml and mean OXT concentration 
for the overall sample was 80.81 pg/ml (SD = 48.81 pg/ml). Three outliers with OXT values 
above 200 pg/ml were identified. Information on these three subjects did not provide a clear 
reason for exclusion of these cases or any indication for invalidity of assessments. Therefore, 
they were retained in the analyses. All further analyses were conducted with the log-
transformed OXT concentrations to assure normal distribution. The bivariate correlation 
between prepartal EPDS scores and OXT concentrations was not significant (r = -.086; p = 
.467). 
The association between OXT concentration in pregnancy and postpartum PPD symptoms 
The test statistics of the logistic regression analyses, with OXT predicting PPD symptoms are 
displayed in Table 2. Plasma OXT level significantly predicted PPD symptoms (Exp (b) = 
.290; p < .05). The coefficient of association between OXT concentration and PPD was below 
one, indicating lower OXT levels in the rPPD group and higher OXT levels in the nPPD 
group. The addition of the prepartal EPDS score as a further covariate in a second analysis did 
not improve the model fit (∆χ2 (1) = 0.302; P > .05). According to the results of descriptive 
statistics, length of gestation was tested as a potential mediator in a third analysis. Length of 
gestation did not predict PPD symptoms (Exp (b) = .931; p > .05) and the model fit did not 
improve either (∆χ2 (1) = 3.507; P > .05). 
With OXT as predictor of PPD symptoms, 83.6% of the sample was classified correctly into 
the nPPD and rPPD group. To visualize the difference in OXT values between the groups, 
mean OXT concentrations are displayed in Figure 2.  
Repeated analyses excluding the three cases with outlying OXT concentrations did not change 
the results. 
Discussion 
In line with our hypothesis, we could show that OXT during pregnancy was negatively 
associated with a positive screen on the EPDS at greater than or equal to 10, indicating a 
higher risk for the development of PPD. This suggests an increased occurrence of depressive 
symptoms in the first two weeks after delivery in individuals with low plasma OXT 
concentrations during pregnancy. The relationship persisted after controlling for prepartal 
EPDS scores.  
Our findings are in agreement with the only human study addressing the link between plasma 
OXT during pregnancy and postpartal maternal behavior. Plasma OXT concentrations during 
pregnancy were found to be positively associated with a set of maternal bonding behaviors, 
such as positive affect and gaze in interactions, as well as cognitive attachment 
representations towards the newborn in the early postpartum period (Feldman et al, 2007). In 
women suffering from PPD the same behaviors are impaired, accompanied by feelings of 
overload and difficulties in emotional attachment development towards their child (Beck, 
2006; Martins and Gaffan, 2000). Correspondingly studies with rodents report deficits in 
maternal behavior, such as less protective behavior and less pup-licking, and longer latencies 
in postpartal onset of maternal behavior in animals with decreased central OXT availability 
(Pedersen et al, 2006; van Leengoed et al, 1987). Non-human primate mothers show 
increased maternal affiliation towards offspring when central OXT is enhanced (Holman and 
Goy, 1995). The present findings are also in agreement with human studies reporting 
relationships between plasma OXT, assessed in the 2nd and 6th month postpartum and 
affectionate maternal behavior during mother-child interactions (Gordon et al, 2010). Again, 
mothers’ OXT concentrations were positively correlated with the behavioral indicators of 
attachment, such as motherese vocalization, affectionate touch and positive affect. As anxiety 
and excessive preoccupation are other important symptoms of PPD, our results also match 
reports of OXT working anxiolytic and enhancing positive emotional affiliation in non-
pregnant humans (Uvnas-Moberg, 1998). There is also evidence for decreased plasma OXT 
concentrations in individuals suffering from Major Depression or reporting increased 
depressive symptoms (Frasch et al, 1995; Ozsoy et al, 2009; Scantamburlo et al, 2007).  
The herein observed prevalence of subjects above cutoff resembles those of other studies 
using the same screening instrument. Here we identified 19.18% of the sample having an 
EPDS score of 10 or more. Other comparable studies found a rate of 20% at 5 days 
postpartum (Bergant et al, 1998) and 16% at two months postpartum (Yim et al, 2009).  
Group comparisons revealed a significantly shorter gestation among women within the rPPD 
group. In women with lower OXT availability in pregnancy the oxytocinergic inhibition of 
the HPA axis could be decreased. Decreased HPA axis inhibition would enhance the 
exponential increase of placental corticotropin-releasing factor that promotes the onset of 
labour (Smith, 1998). However, the length of gestation variable did not reach significance in 
the following prediction of PPD symptoms. It remains to be elucidated, if length of gestation 
plays a mediating role in the relationship between OXT and PPD in samples including 
premature deliveries. 
The range of OXT concentrations found in the present sample, is in line with those of 
previous studies (Dawood et al, 1979; De Geest et al, 1985). One often mentioned issue 
concerning OXT assessment in human samples is that central OXT release is not necessarily 
related to peripheral OXT release and therefore associations between centrally regulated 
psychological variables and peripheral measured OXT should be handled with caution (Jones 
et al, 1983; Landgraf and Neumann, 2004). However, in animals, there are also studies 
accounting for joint control mechanisms of central and peripheral OXT release in context of 
fear-related stress responses (Wotjak et al, 1998) and for autostimulatory effects at the level 
of the hypothalamus, in terms of peripheral OXT release activation by centrally released OXT 
(McKenzie et al, 1995; Neumann et al, 1994). Given the current evidence from animal studies 
and the difficulties in the determination of central OXT release in humans, it appears 
justifiable to revert to peripheral OXT assessment. This is supported by several findings 
reporting relations between peripheral OXT in humans and various psychological constructs, 
all representing aspects of human affiliation and attachment (Feldman et al, 2007; Light et al, 
2004; Tops et al, 2007; Wismer Fries et al, 2005). 
The mechanisms behind the observed association between OXT and PPD symptoms remain 
to be elucidated. Although we cannot rule out residual confounding by unknown factors, the 
prospective design and the inclusion of pre-pregnancy EPDS scores as a covariate make a 
causal relationship imaginable. There already exists evidence that OXT concentrations are 
lower in mothers characterized by depressive symptoms and negative affect during 
pregnancy, when assessed postpartum (Light et al, 2004). Further, OXT is known to reduce 
psychological and physiological stress responses (Heinrichs et al, 2003) and to inhibit 
hyperactive fear-responses of the amygdala (Labuschagne et al, 2010). There is also evidence 
that the properties of endocrine systems during pregnancy have programming functions for 
the postpartal period (Meinlschmidt et al, 2010; Pop et al, 1993). Transferred to our case, the 
interplay between low OXT, its effects on amygdala reactivity and the HPA axis in pregnancy 
could indicate an increased reactivity to stressful stimuli at that time and promote the 
development of depressive symptoms after birth, when mothers are challenged by a bulk of 
potentially stressful new conditions. Additionally, expectations of the social environment and 
the growing demands of the child may promote feelings of fear and insecurity. Notably, a 
study comparing the symptomatology of postpartum and non-postpartum depression found 
more anxious features among the investigated PPD group (Hendrick et al, 2000). As we know 
from animal studies, besides the general importance of OXT in the formation of social bonds 
in females (Insel, 1997), the positive feedback mechanism of the oxytocinergic system is 
supposed to provide long lasting stimulation of maternal behaviors after parturition (DaCosta 
et al, 1996). It may be less efficient, if OXT availability is diminished. Adopted to human 
mothers, this would be reflected by the difficulties depressed mothers have in implementing 
maternal behaviors and forming a relationship with their child (Beck, 1995; Cooper and 
Murray, 1998). Considering the profound physiological challenge caused by endocrinological 
changes over the course of gestation and the following abrupt shift after parturition, it is not 
possible to form a biological model for PPD development, that accounts for all contributing 
factors yet. Future studies should try to experimentally modify OXT concentrations in mid-
pregnancy, to verify, whether OXT during pregnancy contributes to the generation of 
depressive symptoms during the postpartum period. 
There are some limitations of the study. First, our finding needs to be confirmed in future 
studies with more than one OXT assessment over the course of pregnancy to clarify, if the 
relationship is specific to OXT concentrations between the 30th and 34th week of gestation. 
Studies assessing OXT at different stages of gestation report the possibility of individually 
different patterns of OXT fluctuations over time, arguing that there might be a functional 
difference between women with stable OXT levels and those with rising ones (Dawood et al, 
1979; Levine et al, 2007). But high intra-individual stability of values has been reported also 
(Feldman et al, 2007; Leake et al, 1981; van der Post et al, 1997). From our point of view, the 
present results refer to plasma OXT levels between the 30th and 34th week of gestation only, 
as we did not assess potential alterations in peripheral OXT release over the course of 
gestation. Second, the sample consisted of women with mostly medium to high 
socioeconomic status. Consequently results need to be replicated with more heterogenous 
samples. Third, PPD symptoms were assessed by questionnaire (EPDS), which should be 
complemented in future studies by structured or standardized interviews to verify the presence 
of a diagnosis of PPD. It should be noted that as yet, estimations of the sensitivity and 
specificity of the EPDS to detect PPD vary across studies, warranting further attention of this 
issue (Eberhard-Gran et al, 2001; Gaynes et al, 2005; Gibson et al, 2009). Nevertheless there 
are validation studies reporting good sensitivity and specificity values for the EPDS within 
comparable study designs and according to DSM-III and ICD-10 criteria (Harris et al, 1989; 
Jardri et al, 2006). Important to note, our use of the EPDS within a period of 2 weeks 
postpartum does not provide information on the diagnosis of PPD, which requires the 
presence of symptoms for at least two weeks. Moreover, heightened EPDS scores in this early 
postpartum period may still be picking up the tail end of postpartum blues, which itself is a 
risk factor for the development of PPD. Finally, future studies should clarify, if the 
association between prepartal OXT and depressive symptoms during the postpartum period 
remains stable beyond the first two weeks up to several months postpartum and if this 
relationship holds true for individuals with diagnosed episodes of PPD, as not all women with 
increased depressive symptoms after delivery develop a full-blown affective disorder. 
In summary, our findings suggest that OXT is involved in the etiology of depressive 
symptoms during pregnancy and needs to be further elaborated in studies assessing 
neuroendocrinological aspects of PPD. If replicated, the presented results have important 
clinical relevance. Prepartal identification of subjects at risk for PPD could allow for early 
preventive interventions and minimize adverse effects for the physiological and psychological 
wellbeing of mother and child. 
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Titles and Legends to Figures 
Figure 1  Flowchart of study participants. 
Figure 2  Graph shows means + standard error of mean of original oxytocin values in the two 
groups. 
Tables 
Table 1 Sample and group characteristics and tests for group differences. 
total sample nPPD group rPPD group Test between nPPD and 
rPPD 
M (SD) / % M (SD) / % M (SD) / % 
 (N = 73)  (n = 59)  (n = 14) p-value  
maternal age (years) 31.05 (4.70) 31.22 (4.69) 30.36 (4.88) .541a
income category .928b
low 8.70% 8.90% 7.70% 
average/high 73.90% 73.20% 76.90% 
very high 17.40% 17.90% 15.40% 
pre-pregnancy BMI 22.31 (3.47) 22.10 (3.26) 23.32 (4.40) .292a
parity 
primiparae 74.0% 71.20% 85.70% 
multiparae 26.0% 28.80% 14.30% 
length of gestation (weeks) 39.6 (1.2) 39.7 (1.1) 39.1 (1.4) .044a
birth mode 
ceserean section 23.3% 23.70% 21.40% 
mother  is nursing 90.0% 89.7% 92.3% 
infant birth weight (g) 3338.56 (378.44) 3345.93 (359.21) 3307.50 (465.02) .735a
infant sex 
female 46.6% 50.8% 28.6% 
male 53.4% 49.2% 71.4% 
Monthly income categories low = 0-3750 swiss franks, average/high = 3750-11250 swiss franks, very high = above 11250 swiss franks; 
nPPD = no risk for Postpartum Depression; rPPD = at risk for Postpartum Depression; BMI = Body-Mass-Index. 
at-test 
bχ2-test
Table 2  Binary logistic regression analysis fort he prediction of being at risk for Postpartal Depression. 
model statistics predictor statistics 
χ2 (df) P R²NK -2 LL Wald‘s Χ² (df) p Exp(b) 95% CI for Exp(b) 
First analysis 6.195 (1) .013 0.130 65.169 
plasma oxytocin 5.555 (1) .018 0.290 0.103 - 0.812 
Second analysis 6.497 (2) .039 0.137 64.867 
plasma oxytocin 5.366 (1) .210 0.294 0.105 - 0.828 
 prepartal EPDS score 0.299 (1) .584 1.254 0.557 - 2.828 
Change of model fit compared to first analysis: ∆ χ2 (1) = 0.302; p = .583 
Third analysis 9.702 (2) .008 0.200 61.662 
plasma oxytocin 5.250 (1) .022 0.294 0.103 - 0.838 
 length of gestation 3.447 (1) .063 0.931 0.864 - 1.004 
Change of model fit compared to first analysis: ∆ χ2 (1) = 3.507; p = .061 
         R²NK = Nagelkerke R²; -2 LL = -2 Log Likelihood (deviance); χ2 = Chi-Square; EPDS = Edinburgh Postnatal Depression Scale.
	




( -- - Multiple outcome N = 1 
- Current diagnosis of affective disorder N = 1 
Eligible participants after screening and interview 
(N = 98) 
- Discontinued study-participation before birth 
N=1 
--
- No OXT data available due to non-participation 
- or insufficient amounts of plasma N = 14 
' 
( - Preterm delivery N = 1 
- Infant death after birth N = 1 
Eligible participants after live singleton outcome 
(N = 77) 
--
- No postpartal EPOS assessment due to 
-
' 
( discontinued study-participation after birth N = 4 
lncluded in analysis (all required data available) 
(N = 73) 












































at risk for PPD 
Figure 2 Graph shows individual oxytocin concentrations in the 
two groups and group means. Oxytocin values are shown on a 
logarithmic scale. 
